-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Chelidonine
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/476-32-4.gif)
| Category | Influenza Virus |
| CAS | 476-32-4 |
| Description | Chelidonine, coming from the herbs of Chelidonium majus L, exhibits anti‑migratory and anti‑invasive effects in MDA‑MB‑231 cells, by suppressing COL‑I‑induced integrin signaling, through inhibiting the formation of the IPP complex and subsequent down‑regulation of IPP downstream signaling molecules, such as Akt and ERK1/2. These results suggest that Chelidonine may be a potential therapeutic agent against metastasis of invasive human cancer cells. Chelidonine is a promising model compound for overcoming MDR and for enhancing cytotoxicity of chemotherapeutics, especially against leukaemia cells. Its efficacy needs to be confirmed in animal models. |
Product Information
| Synonyms | chelidoniny; helidonine; khelidonin; STYLOPHORIN; STYLOPHORINE; STYLOPHORON; CHELIDONIN; (+)-CHELIDONINE |
| IUPAC Name | (1S,12S,13R)-24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-2,4(8),9,14(22),15,17(21)-hexaen-12-ol |
| Molecular Weight | 353.37 |
| Molecular Formula | C20H19NO5 |
| Canonical SMILES | CN1CC2=C(C=CC3=C2OCO3)C4C1C5=CC6=C(C=C5CC4O)OCO6 |
| InChI | InChI=1S/C20H19NO5/c1-21-7-13-11(2-3-15-20(13)26-9-23-15)18-14(22)4-10-5-16-17(25-8-24-16)6-12(10)19(18)21/h2-3,5-6,14,18-19,22H,4,7-9H2,1H3/t14-,18-,19+/m0/s1 |
| InChIKey | GHKISGDRQRSCII-ZOCIIQOWSA-N |
| Boiling Point | 507.4±50.0 °C at 760 mmHg |
| Melting Point | 135-140°C |
| Flash Point | 260.7±30.1 °C |
| Purity | >98% |
| Density | 1.4±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 100 mg/mL(282.99 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution |
| Appearance | Cryst. |
| Application | Anti‑migratory/anti‑invasive/anti-cancer |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 560 |
| Exact Mass | 353.12632271 |
| Index Of Refraction | 1.667 |
| In Vitro | Chelidonine (5, 10 and 20 μM; 3-4 days) causes lesions and ventral curling in Dugesia japonica; and significantly decreases Djmcm2 expression at 20 μM but no reduction is observed at 5 and 10 μM; as well as prevents cell cycle progression of stem cells. Chelidonine (0-3 μg/mL; 48 h) has cytotoxic activity against melanoma cell lines, Chelidonine (1, 2 and 3 μg/mL; 24 h) decreases mitochondrial membrane potential (MMP) in 50% of A-375 cells at 1 and 1.5 g/mL, and 62% at 3 μg/mL. |
| PSA | 60.39000 |
| Target | Apoptosis; Influenza Virus |
| Vapor Pressure | 0.0±1.4 mmHg at 25°C |
| XLogP3-AA | 2.2 |
